Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADMA BIOLOGICS, INC.ADMA · Entity 4477 | CFO and Treasurer | February 19, 2026 | February 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADMA BIOLOGICS, INC.
Report date February 19, 2026 · Filed February 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 232,940 |
Reported balance
After 2026-02-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-19 · Tax withholding · Disposed 6,479 · Balance 232,940 F1: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities. F2: Includes, as of the transaction date, (i) 46,671 unvested RSUs out of 62,227 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 54,300 unvested RSUs granted on July 24, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; F3: (continued from footnote 2) (iii) 37,500 unvested RSUs granted by the Company on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; F4: (continued from footnote 3) (iv) 50,000 unvested RSUs, granted by the Company on June 26, 2023, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 44,469 shares acquired in open market purchases and pursuant to the vesting of RSUs after the withholding of shares to cover applicable taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.
F2: Includes, as of the transaction date, (i) 46,671 unvested RSUs out of 62,227 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 54,300 unvested RSUs granted on July 24, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
F3: (continued from footnote 2) (iii) 37,500 unvested RSUs granted by the Company on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
F4: (continued from footnote 3) (iv) 50,000 unvested RSUs, granted by the Company on June 26, 2023, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 44,469 shares acquired in open market purchases and pursuant to the vesting of RSUs after the withholding of shares to cover applicable taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2026 Filed Feb 23, 2026 21:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 6,479 | $16.32 | $105,737.28 |
DisclosureSEC source: 0001140361-26-006460 · form4.xml · nonDerivative · entry 1 Tade Brad L. · CIK 0002030561 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,940 F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities. F2 · balance_after: Includes, as of the transaction date, (i) 46,671 unvested RSUs out of 62,227 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 54,300 unvested RSUs granted on July 24, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; F3 · balance_after: (continued from footnote 2) (iii) 37,500 unvested RSUs granted by the Company on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; F4 · balance_after: (continued from footnote 3) (iv) 50,000 unvested RSUs, granted by the Company on June 26, 2023, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 44,469 shares acquired in open market purchases and pursuant to the vesting of RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| July 24, 2025 Filed Jul 28, 2025 21:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 7,123 | $17.31 | $123,299.13 |
DisclosureSEC source: 0001140361-25-027641 · form4.xml · nonDerivative · entry 1 Tade Brad L. · CIK 0002030561 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,419 F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities. F2 · balance_after: Includes, as of the transaction date, (i) 62,227 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 54,300 unvested RSUs granted on July 24, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; F3 · balance_after: (continued from footnote 2) (iii) 37,500 unvested RSUs granted by the Company on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; F4 · balance_after: (continued from footnote 3) (iv) 50,000 unvested RSUs, granted by the Company on June 26, 2023, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 35,392 shares acquired in open market purchases and pursuant to the vesting of RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 21:02 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 9,838 | $18.40 | $181,019.20 |
DisclosureSEC source: 0001140361-25-024252 · form4.xml · nonDerivative · entry 1 Tade Brad L. · CIK 0002030561 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,542 F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities. F2 · balance_after: Includes, as of the transaction date, (i) 62,227 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 72,400 unvested RSUs granted on July 24, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; F3 · balance_after: (continued from footnote 2) (iii) 37,500 unvested RSUs granted by the Company on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; F4 · balance_after: (continued from footnote 3) (iv) 50,000 unvested RSUs, granted by the Company on June 26, 2023, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 24,415 shares acquired in open market purchases and pursuant to the vesting of RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| February 26, 2025 Filed Feb 27, 2025 21:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 5,280 | $15.78 | $83,318.40 |
DisclosureSEC source: 0001140361-25-006384 · form4.xml · nonDerivative · entry 1 Tade Brad L. · CIK 0002030561 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,380 F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities. F2 · balance_after: Includes, as of the transaction date, (i) 62,227 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 72,400 RSUs granted on July 24, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; F3 · balance_after: (continued from footnote 2) (iii) 37,500 unvested RSUs granted by the Company on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; F4 · balance_after: (continued from footnote 3) (iv) 56,250 unvested RSUs, granted by the Company on June 26, 2023, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 28,003 shares acquired in open market purchases and pursuant to the vesting of RSUs after the withholding of shares to cover applicable taxes. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:01 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 93,023 | $0.00 Strike: $16.07 | $0.00 |
DisclosureSEC source: 0001140361-25-005536 · form4.xml · derivative · entry 2 Tade Brad L. · CIK 0002030561 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,023 Underlying: Common Stock · 93,023 shares Expires 2035-02-19 F5 · derivative.exercise_date: The options vest over four years with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 19, 2029 in accordance with the Plan. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:01 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 62,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-005536 · form4.xml · nonDerivative · entry 1 Tade Brad L. · CIK 0002030561 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 261,660 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the reporting person's continued service as of the applicable vesting date. F2 · balance_after: Includes, as of the transaction date, (i) 62,227 unvested RSUs granted on February 19, 2025 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 72,400 RSUs granted on July 24, 2024, that will vest in four equal installments (25% per installment) on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting; F3 · balance_after: (continued from footnote 2) (iii) 56,250 unvested RSUs, granted by the Company on June 26, 2023, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting; F4 · balance_after: (continued from footnote 3) (iv) 50,000 RSUs, all of which are currently unvested, granted by the Company on February 26, 2024, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting; and (v) 20,783 shares acquired in open market purchases and pursuant to the vesting of RSUs. Read SEC document |
| November 22, 2024 Filed Nov 22, 2024 21:05 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | SaleCommon Stock | 15,000 | $21.15 | $317,250.00 |
DisclosureSEC source: 0001140361-24-047702 · form4.xml · nonDerivative · entry 1 Tade Brad L. · CIK 0002030561 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,433 F1 · shares: These shares represent restricted stock units ("RSUs") that were granted on June 26, 2023 and vested on June 26, 2024. F2 · balance_after: Includes, as of the transaction date, (i) 72,400 RSUs granted on July 24, 2024, that will vest in four equal installments (25% per installment) on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting; F3 · balance_after: (continued from footnote 2) (ii) 56,250 unvested RSUs, granted by the Company on June 26, 2023, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting; F4 · balance_after: (continued from footnote 3) (iii) 50,000 RSUs, all of which are currently unvested, granted by the Company on February 26, 2024, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting; and (iv) 20,783 shares acquired in open market purchases and pursuant to the vesting of RSUs. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 21:05 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 115,100 | $0.00 Strike: $13.58 | $0.00 |
DisclosureSEC source: 0001140361-24-034471 · form4.xml · derivative · entry 2 Tade Brad L. · CIK 0002030561 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,100 Underlying: Common Stock · 115,100 shares Expires 2034-07-24 F4 · derivative.exercise_date: The options vest over four years with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on the four-year anniversary of the grant date. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 21:05 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 72,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-034471 · form4.xml · nonDerivative · entry 1 Tade Brad L. · CIK 0002030561 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,433 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in four equal installments (25% per installment) on each annual anniversary of the date of grant over four years, in each case under the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan") subject to the reporting person's continued service as of the applicable vesting date. F2 · balance_after: Includes, as of the transaction date, (i) 72,400 RSUs granted on July 24, 2024 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 75,000 unvested RSUs, granted by the Company on June 26, 2023, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting; F3 · balance_after: (Continued from Footnote 2 above) (iii) 50,000 RSUs, all of which are currently unvested, granted by the Company on February 26, 2024, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting; and (iv) 17,033 shares acquired in open market purchases and pursuant to the vesting of RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.